Valuation: PYC Therapeutics Limited

Market Cap 2.1B 1.49B 1.29B 1.21B 1.1B 2.07B 142B 14.22B 5.55B 70.99B 5.58B 5.46B 237B P/E 2026 *
-29.8x
P/E 2027 * -23.3x
Enterprise Value 1.44B 1.02B 882M 826M 753M 1.42B 97.06B 9.73B 3.8B 48.59B 3.82B 3.74B 162B EV / Sales 2026 *
393x
EV / Sales 2027 * -
Free-Float
70.64%
Yield 2026 *
-
Yield 2027 * -
1 day-0.47%
1 week+4.90%
Current month+25.88%
1 month+41.25%
3 months+48.10%
6 months+42.19%
Current year+29.31%
1 week 2.02
Extreme 2.02
2.23
1 month 1.52
Extreme 1.515
2.23
Current year 1.04
Extreme 1.045
2.23
1 year 0.85
Extreme 0.847
2.23
3 years 0.52
Extreme 0.52
2.23
5 years 0.5
Extreme 0.5
2.23
10 years 0.14
Extreme 0.14
2.23
Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Chairman 66 18/11/2025
Date Insider Type Main position Quantity % Market Cap.
23/12/25 Free

Chairman

2,000,000 0.3429%
26/11/25 Buy

Chief Executive Officer

133,350 0.0229%
27/2/25
Australia Land Pty Ltd.
BuyCompany 28,000,000 6.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%+4.90%+69.17%+296.30% 1.49B
-2.62%-2.69%+0.94%+12.67% 49.24B
-0.47%-2.78%+453.72%+564.83% 43.3B
-3.05%-0.54%+11.85%+69.68% 40.48B
-0.56%-0.10%+25.91%+8.34% 39.75B
0.00%+3.59%+20.51%+48.00% 32.67B
-0.90%-4.33% - - 16.23B
-0.79%-3.21%+24.65%+115.25% 16.24B
+0.43%+0.86%+4.27%+22.10% 14.04B
-0.44%+4.84%+79.99%+29.29% 13.43B
Average -0.79%+2.16%+76.78%+129.60% 26.69B
Weighted average by Cap. -1.16%+2.70%+93.79%+130.93%

Financials

2026 *2027 *
Net sales 3.67M 2.59M 2.24M 2.1M 1.92M 3.61M 247M 24.77M 9.67M 124M 9.72M 9.51M 413M -
Net income -57.43M -40.55M -35.15M -32.95M -30.04M -56.53M -3.87B -388M -151M -1.94B -152M -149M -6.46B -85.75M -60.54M -52.48M -49.19M -44.85M -84.4M -5.78B -579M -226M -2.89B -227M -222M -9.65B
Net Debt -664M -469M -407M -381M -347M -654M -44.76B -4.49B -1.75B -22.41B -1.76B -1.72B -74.74B -579M -409M -354M -332M -303M -570M -39B -3.91B -1.53B -19.52B -1.53B -1.5B -65.12B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
14/08/26 $2.140 -0.47% 1,632,040
13/08/26 $2.150 -1.83% 1,869,473
12/08/26 $2.190 +2.34% 1,220,227
11/08/26 $2.140 +2.39% 2,223,443
10/08/26 $2.090 +2.45% 1,174,447
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.150AUD
Average target price
3.752AUD
Spread / Average Target
+74.51%

Quarterly revenue - Rate of surprise